A Case of Sustained Objective Response of Recurrent/Progressive Diffuse Intrinsic Pontine Glioma with Phenylbutyrate and Targeted Agents

Burzynski, Stanislaw R.; Burzynski, Gregory S.; Brookman, Sheldon

doi:10.4236/jct.2015.61006

Cited by 5 publications

(5 citation statements)

References 20 publications

(24 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CDA-2, a perfect cancer drug consisting of natural metabolites active as DIs, DHIs and an anti-cachexia chemical, is the drug of choice for MDS. Phenylbutyrate, a moderately active DHI, is the drug effective against malignant brain tumors which are unresponsive to conventional therapies due to elevated level of CSCs [59,60]. CDA formulations with DIs and DHIs as active ingredients are indeed excellent cancer drugs.…”

Section: War On Cancermentioning

confidence: 99%

CDA Formulations to Fulfill Cancer Moonshot and to Win the War on Cancer

Liau¹,

Craig²,

Baker³

2023

Int J Res Oncol

View full text Add to dashboard Cite

The objective of this study is to call for approval of cell differentiation agent (CDA) formulations as the right cancer drugs to save cancer patients. Moonshot was a presidential project to set a classic record of success attributable to the right approach and war on cancer was another presidential project to set a classic record of failure attributable to the wrong approach. Cancer moonshot was brought up by President Biden to urge health profession to rely on right approaches to save cancer patients. Perpetual replication of cancer cells (CCs) is the most outstanding feature of cancer. Naturally, killing of replicating CCs becomes the top choice of cancer establishments to combat cancer. Killing of CCs is actually a wrong approach of cancer therapy, because cancer is caused by wound unhealing due to the collapse of chemo-surveillance, which is a natural mechanism to ensure perfection of wound healing. Killing of CCs by cytotoxic agents promotes cancer stem cells (CSCs) to proliferate in order to repair the damages created by cytotoxic agents, eventually pushing CSCs to reach a high proportion to become unresponsive to further treatments. Killing of CCs is a wrong approach that causes the failure of cancer solution. To save cancer patients, we have to drastically change past practices. Apparently, wound healing process is the right approach of cancer therapy. Induction of terminal differentiation of PSCs is the most critical mechanism of wound healing, which is achieved by differentiation inducers (DIs) and differentiation helper inducers (DHIs). CDA is a collective term of the preparations consisting of different proportions of DIs and DHIs. Therefore, CDA formulations are the best solution of cancer to fulfill cancer moonshot and to win the war on cancer. CDA formulations display the features as pro-wound healing that can eliminate both CSCs and CCs by inducing these cells to undergo terminal differentiation, and to restore the functionality of chemo-surveillance, which is the creation of the nature to prevent the buildup of cells with abnormal MEs. A perfect cancer drug must have the ability to eliminate both CSCs and CCs, and to restore the functionality of chemo-surveillance. CDA formulations fit the description as perfect cancer drugs to fulfill cancer moonshot and to win the war on cancer.

show abstract

Section: War On Cancermentioning

confidence: 99%

CDA Formulations to Fulfill Cancer Moonshot and to Win the War on Cancer

Liau¹,

Craig²,

Baker³

2023

Int J Res Oncol

View full text Add to dashboard Cite

show abstract

“…Imatinib mesylate, a DHI, is the standard care of chronic myeloid leukemia. Phenylbutyrate, the first DHI of our discovery which was only moderately active [33], has been dexterously employed by Burzynski to cure malignant brain cancer [34,35]. Malignant brain tumors are untreatable by therapies based on cell killing because these tumors are enriched with CSCs [36].…”

Section: Winning Formulas To Fulfill Cancer Moonshotmentioning

confidence: 99%

Winning Formulas to Fulfill Cancer Moonshot

Liau¹,

Fruehauf²

2022

Int J Res Oncol

View full text Add to dashboard Cite

The objective of this study was to develop winning formulas to fulfill cancer moonshot declared by President Biden on Sept. 12, 2022, the 60th anniversary of the moonshot speech of President Kennedy. The intention of President Biden was to use the spirit of successful moonshot project to salvage the failure of war on cancer project declared by President Nixon in 1971 [1]. Cancer therapies based on killing of cancer cells were the choice of cancer establishments in the past. The choice of killing cancer cells is understandable because the perpetual replication of cancer cells constitutes the most outstanding feature of cancer. Cancer is contributed by multiple factors. Factors other than replication of cancer cells also play essential roles on the development of cancer. Cancer arises as a consequence of wound not healing properly due to the collapse of chemo-surveillance, thus allowing Progenitor Stem Cells (PSCs) to evolve into Cancer Stem Cells (CSCs), and then to progress to faster growing Cancer Cells (CCs) through activation of oncogenes and/or inactivation suppressor genes. Cell killing creates more wounds to aggravate the already bad situation on the functionality of chemo-surveillance, which is an important mechanism to suppress the build-up of cells with abnormal Methylation Enzymes (MEs) that include PSCs, CSCs, and CCs. PSCs and their immediate derivatives CSCs are protected by drug resistant and anti-apoptosis mechanisms. Cytotoxic agents can wipe out CCs but cannot affect CSCs. The damage to chemo-surveillance contributed by cell killing agents allows CSCs to become dominant cells to cause he failure of cancer therapy, thus losing the war on cancer. Cell Differentiation Agent (CDA) formulations are the preparations consisting of Differentiation Inducers (DIs) and Differentiation Helper Inducers (DHIs), plus phenylacetylglutamine as an anti-cachexia agent. Such preparations are perfect cancer drugs to take out both CCs and CSCs by the induction of terminal differentiation through destabilization of abnormal MEs, and to restore the functionality of chemo-surveillance. Cancer therapies mediated by CDA formulations are the nature’s choice to combat cancer that can fulfill the goal of President Biden’s cancer moonshot. CDA formulations, however, cannot make the tumor to disappear, which can be easily accomplished by therapies based on cell killing. President Biden’s goal is very modest, requiring reduction of cancer mortality 50% in 25 years. That goal can be easily accomplished by winning formulas that include CDA formulations and therapies to eliminate or to kill CCs. We offer the following winning formulas: 1. Therapy with CDA-CSC, a preparation made up by an approved DI and an approved DHI, to eradicate CSCs and CCs by the induction of terminal differentiation and to restore the functionality of chemo-surveillance, followed by the surgical removal of the residual tumor. 2. Surgical removal of the primary tumor, followed by the administration of CDA-CSC to prevent recurrence and metastasis, and to restore the functionality of chemo-surveillance. 3. Radiotherapy, immunotherapy, or chemotherapy to kill CCs, followed by the administration of CDA-CSC to eradicate CSCs and to restore the functionality of chemo-surveillance.

show abstract

“…Nevertheless, it has demonstrated therapeutic efficacy on often untreatable brain tumors [44,45]. It's benefits were enhanced when used in combination with STIs [46,47], which were effective in µM concentrations [16].…”

Section: Destabilization Of Abnormal Mes As An Effective Approach For Cancer Therapymentioning

confidence: 99%